Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
05:29pm, Monday, 13'th Jun 2022 Zacks Investment Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary re
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
03:03pm, Monday, 13'th Jun 2022
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary re
Sanofi, GSK Covid Booster Triggers ‘Strong Immune Response' Against Multiple Variants Including Omicron
06:09am, Monday, 13'th Jun 2022
The shot provoked a stronger immune response against omicron than a booster dose of Pfizer's vaccine, Sanofi said.
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
12:41pm, Friday, 10'th Jun 2022 Zacks Investment Research
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
Ergomed appoints former GSK and Sanofi executive to board
04:02am, Friday, 10'th Jun 2022
Ergomed PLC (AIM:ERGO, ETR:2EM) said Anne Whitaker will join its board as an independent non-executive director after the pharmaceutical industry service provider's AGM on Friday. She has worked acro
What Could a Recession Mean for Healthcare Stocks?
03:30pm, Thursday, 09'th Jun 2022 The Motley Fool
It depends on which subsector you're talking about.
What Could a Recession Mean for Healthcare Stocks?
11:30am, Thursday, 09'th Jun 2022
It depends on which subsector you're talking about.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
01:13pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
10:32am, Wednesday, 08'th Jun 2022
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
07:25pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.
Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study
01:48pm, Monday, 06'th Jun 2022 Zacks Investment Research
Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
07:42pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
Why Regeneron Wasn't a Healthy Stock Today
10:30pm, Thursday, 02'nd Jun 2022 The Motley Fool
The company is forking over $900 million in an upfront payment to fully own a cancer drug.
Regeneron to buy Sanofi's cancer drug in $1B deal
06:36pm, Thursday, 02'nd Jun 2022
Regeneron CEO Leonard Schleifer on the decision to spend $1.1B to buy Sanofi's cancer drug portfolio. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman and Dan Nathan.
Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug
03:24pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.
